Urology Times 50 Innovations Series: Multiparametric MRI in prostate cancer
“From a screening perspective, mpMRI really has changed how we evaluate men at risk for prostate cancer. It has improved the selection of men for biopsy and certainly improved our diagnostic rates,” says William P. Parker, MD.
EP: 1.Urology Times 50 Innovations Series: PSA testing
EP: 2.Urology Times 50 Innovations Series: Testosterone therapy
EP: 3.Urology Times 50 Innovations Series: Stem cell–derived therapy for stress urinary incontinence
EP: 4.Urology Times 50 Innovations Series: Tissue engineering and regenerative medicine
EP: 5.50th Anniversary Innovation Celebration: The midurethral sling for stress urinary incontinence
EP: 6.Urology Times 50 Innovations Series: Genetic testing for prostate cancer
EP: 7.Urology Times 50 Innovations Series: Onabotulinumtoxin A for overactive bladder
EP: 8.Urology Times 50 Innovations Series: Clean intermittent catheterization
EP: 9.Urology Times 50 Innovations Series: Viagra for treatment of erectile dysfunction
EP: 10.Urology Times 50 Innovations Series: Active surveillance for prostate cancer
EP: 11.Urology Times 50 Innovations Series: BCG therapy for bladder cancer
EP: 12.Urology Times 50 Innovations Series: Extracorporeal shock wave lithotripsy for stones
EP: 13.Urology Times 50 Innovations Series: Treatment of female hypoactive sexual desire disorder
EP: 14.Urology Times 50 Innovations Series: Cryotherapy for kidney and prostate cancer
EP: 15.Urology Times 50 Innovations Series: Intralesional therapies for Peyronie's disease
EP: 16.Urology Times 50 Innovations Series: Radiation therapy for prostate cancer
EP: 17.Urology Times 50 Innovations Series: β3 agonists for overactive bladder
EP: 18.Urology Times 50 Innovations Series: Microsurgical testicular sperm extraction
EP: 19.Urology Times 50 Innovations Series: Anatomic radical prostatectomy
EP: 20.Urology Times 50 Innovations Series: Dr. Kelvin Moses on sipuleucel-T for mCRPC
EP: 21.Urology Times 50 Innovations Series: Dr. Jennifer Linehan on HIFU for prostate cancer
EP: 22.Urology Times 50 Innovations Series: Transrectal ultrasound-based prostate biopsy
EP: 23.Urology Times 50 Innovations Series: Neobladder reconstruction
EP: 24.Urology Times 50 Innovations Series: Multichannel urodynamics
EP: 25.Urology Times 50 Innovations Series: Treatments for male infertility
EP: 26.Urology Times 50 Innovations Series: Urinary molecular biomarkers in prostate cancer
EP: 27.Urology Times 50 Innovations Series: Blue light cystoscopy for the detection of bladder cancer
EP: 28.Urology Times 50 Innovations Series: LHRH analogues in prostate cancer
EP: 29.Urology Times 50 Innovations Series: Advancements in vesicovaginal fistula repair
EP: 30.Urology Times 50 Innovations Series: Artificial urinary sphincter
EP: 31.Urology Times 50 Innovations Series: PSMA-PET imaging in prostate cancer
EP: 32.Urology Times 50 Innovations Series: Sacral neuromodulation
EP: 33.Urology Times 50 Innovations Series: Penile prostheses
EP: 34.Urology Times 50 Innovations Series: Multiparametric MRI in prostate cancer
EP: 35.Urology Times 50 Innovations Series: Intracavernosal injections for erectile dysfunction
EP: 36.Urology Times 50 Innovations Series: Bulking injections for stress urinary incontinence
EP: 37.Dr. Gill explains the importance of BPH treatment innovations to urology
EP: 38.50th Anniversary Innovation Celebration: Buccal mucosa grafts for urethral strictures
Urology Times® is celebrating its 50th anniversary in 2022. To mark the occasion, we are highlighting 50 of the top innovations and developments that have transformed the field of urology over the past 50 years. In this installment, William P. Parker, MD, discusses the use of multiparametric MRI (mpMRI) in prostate cancer. Parker is a practicing urologist at The University of Kanas Health System and an assistant professor at the University of Kansas Medical Center.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
